A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane

International Journal of Clinical Oncology, 05/24/2012

TSU–68 monotherapy produced clinical benefit in only 5 % of the patients and did not produce objective overall response; however, the treatment was well tolerated. Further evaluation of the efficacy of TSU–68 will be worthwhile because the mRNA levels of CD31, Flt–1 and Flk–1/KDR decreased in 4 patients.

Print Article Summary Cat 2 CME Report